WO2017207616A1 - Diagnostic du cancer par détection d'auto-anticorps dirigés contre la protéine de liaison à la boîte y (yb-1) - Google Patents

Diagnostic du cancer par détection d'auto-anticorps dirigés contre la protéine de liaison à la boîte y (yb-1) Download PDF

Info

Publication number
WO2017207616A1
WO2017207616A1 PCT/EP2017/063129 EP2017063129W WO2017207616A1 WO 2017207616 A1 WO2017207616 A1 WO 2017207616A1 EP 2017063129 W EP2017063129 W EP 2017063129W WO 2017207616 A1 WO2017207616 A1 WO 2017207616A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
cancer
level
sample
antibody
Prior art date
Application number
PCT/EP2017/063129
Other languages
English (en)
Other versions
WO2017207616A9 (fr
Inventor
Harald Heidecke
Peter Mertens
Kai Schulze-Forster
Original Assignee
Celltrend Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrend Gmbh filed Critical Celltrend Gmbh
Publication of WO2017207616A1 publication Critical patent/WO2017207616A1/fr
Publication of WO2017207616A9 publication Critical patent/WO2017207616A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Definitions

  • the present invention is in the field of medicine, in particular to the field diagnostics and prognosis of cancer, particularly ovarian cancer. Furthermore, it relates to methods, means and kits for diagnosis of cancer and for the detection of YB-1 antibodies in samples of patients.
  • ovarian cancer According to the American Cancer Society ovarian cancer is expected to account for over 22,000 new cancer diagnoses and more than 14,000 deaths in 2013 in the US alone. Of the gynaecologic malignancies, ovarian cancer has the highest mortality rate. In early stages of the disease, ovarian cancer is nearly asymptomatic. Hence, a large portion of the patients present with clinically advanced stages of ovarian cancer. However, the 5-year survival rate for patients diagnosed with early-stage disease is often >90%, but it is ⁇ 20% for advanced- stage disease, underscoring the importance of early detection.
  • ovarian cancer antigen 125 (CA125) (Coticchia et al. (2008), J. Natl. Compr. Cane. Netw. 6(8):795-802).
  • Serum CA125 levels are elevated in 3 ⁇ 480% of patients with advanced- stage epithelial ovarian cancer but are increased in only 50—60% of patients with early-stage disease. Serum CA125 levels may be falsely elevated in women with any i.p.
  • ovarian cancer pathology resulting in irritation of the serosa of the peritoneum or pericardium, uterine fibroids, renal disorders, and normal menses.
  • serum CA125 levels do not predict the outcome of biomarkers include, for example, Human Epidymis Protein 4 (HE4) and Mesothelin (Sarojini et al. (2012), Journal of Oncology 102, Article ID 709049).
  • Severeness of ovarian cancer is categorized by the grade and stage of tumorization. This nowadays can only be performed by evaluation of the tumors under or after surgical treatment or by combining marker evaluation and (histological) evaluation of tissue. Staging may be very important because ovarian cancers have different prognosis at different stages and may be treated differently.
  • the accuracy of the staging may determine whether or not a patient will be cured. If the cancer isn't accurately staged, then cancer that has spread outside the ovary might be missed and not treated. Once a stage has been given it does not change, even when the cancer comes back or spreads to new locations in the body.
  • FIGO staging system uses information obtained after surgery, which can include a total abdominal hysterectomy, removal of (usually) both ovaries and fallopian tubes, (usually) the omentum, and pelvic (peritoneal) washings for cytopathology.
  • the AJCC stage is the same as the FIGO stage.
  • the AJCC staging system describes the extent of the primary Tumor (T), the absence or presence of metastasis to nearby lymph Nodes (N), and the absence or presence of distant Metastasis (M).
  • Stage I limited to one or both ovaries
  • LA involves one ovary; capsule intact; no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings
  • LB involves both ovaries; capsule intact; no tumor on ovarian surface; negative washings
  • LC tumor limited to ovaries with any of the following: capsule ruptured, tumor on ovarian surface, positive washings
  • Para-aortic lymph node metastases are considered regional lymph nodes (Stage IIIC). As there is only one para-aortic lymph node intervening before the thoracic duct on the right side of the body, the ovarian cancer can rapidly spread to distant sites such as the lung.
  • the AJCC/TNM staging system includes three categories for ovarian cancer, T, N and M.
  • the T category contains three other subcategories, Tl , T2 and T3, each of them being classified according to the place where the tumor has developed (in one or both ovaries, inside or outside the ovary).
  • the Tl category of ovarian cancer describes ovarian tumors that are confined to the ovaries, and which may affect one or both of them.
  • the sub-subcategory Tl a is used to stage cancer that is found in only one ovary, which has left the capsule intact and which cannot be found in the fluid taken from the pelvis. Cancer that has not affected the capsule, is confined to the inside of the ovaries and cannot be found in the fluid taken from the pelvis but has affected both ovaries is staged as Tib.
  • Tic category describes a type of tumor that can affect one or both ovaries, and which has grown through the capsule of an ovary or it is present in the fluid taken from the pelvis.
  • T2 is a more advanced stage of cancer. In this case, the tumor has grown in one or both ovaries and is spread to the uterus, fallopian tubes or other pelvic tissues.
  • Stage T2a is used to describe a cancerous tumor that has spread to the uterus or the fallopian tubes (or both) but which is not present in the fluid taken from the pelvis.
  • Stages T2b and T2c indicate cancer that metastasized to other pelvic tissues than the uterus and fallopian tubes and which cannot be seen in the fluid taken from the pelvis, respectively tumors that spread to any of the pelvic tissues (including uterus and fallopian tubes) but which can also be found in the fluid taken from the pelvis.
  • T3 is the stage used to describe cancer that has spread to the peritoneum. This stage provides information on the size of the metastatic tumors (tumors that are located in other areas of the body, but are caused by ovarian cancer).
  • T3a can be very small, visible only under the microscope (T3a), visible but not larger than 2 centimeters (T3b) and bigger than 2 or not spread to nearby lymph nodes.
  • N categories NO which indicates that the cancerous tumors have not affected the lymph nodes
  • Nl which indicates the involvement of lymph nodes close to the tumor.
  • the M categories in the AJCC/TNM staging system provide information on whether the ovarian cancer has metastasized to distant organs such as liver or lungs. MO indicates that the cancer did not spread to distant organs and Ml category is used for cancer that has spread to other organs of the body.
  • the AJCC/TNM staging system also contains a Tx and a Nx sub-category which indicates that the extent of the tumor cannot be described because of insufficient data, respectively the involvement of the lymph nodes cannot be described because of the same reason.
  • the ovarian cancer stages are made up by combining the TNM categories in the following manner:
  • Stage I T1+N0+M0; Li: Tl a+N0+M0; IB: Tlb+N0+M0; IC: Tl c+N0+M0;
  • ovarian cancer In addition to being staged, like all cancers ovarian cancer is also graded.
  • the histologic grade of a tumor measures how abnormal or malignant its cells look under the microscope. There are four grades indicating the likelihood of the cancer to spread and the higher the grade, the more likely for this to occur.
  • Grade 0 is used to describe non-invasive tumors. Grade 0 cancers are also referred to as borderline tumors. Grade 1 tumors have cells that are well differentiated (look very similar to the normal tissue) and are the ones with the best prognosis. Grade 2 tumors are also called moderately well differentiated and they are made up by cells that resemble the normal tissue. Grade 3 tumors have the worst prognosis and their cells are abnormal, referred to as poorly differentiated.
  • Grade 3 tumors have the worst prognosis and their cells are abnormal, referred to as poorly differentiated.
  • YB-1 The pi 8 fragment of Y binding protein (YB-1) has been shown to have a high specific prevalence in malignancies; see Tacke et al.: High prevalence of Y-boxprotein-l/pl 8 fragment in plasma of patients with malignancies of different origin, BMC Cancer 2014, 14:33.
  • YB-1 Y binding protein
  • levels of such antibodies are lower in samples of patients suffering from cancer, in particular ovarian cancer.
  • the higher the level of antibodies against YB-1 in patients suffering from cancer the higher the chance that the patient will respond to chemotherapy.
  • the data presented herein demonstrate that auto-antibodies directed against YB-1 provide an advantageous tool for diagnosis and treatment of cancer.
  • the present application relates to a method for diagnosis of cancer, comprising the steps of (i) determining the level of antibodies against Y box binding protein 1 (YB-1) in a sample from a subject to be diagnosed, and (ii) comparing the determined level in the sample to a control level of YB-1 antibodies derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of cancer in the subject to be diagnosed
  • YB-1 Y box binding protein 1
  • the invention further pertains to a method for diagnosis of cancer, wherein a level of anti- YB-1 antibodies in the sample of the patient to be diagnosed of less than 0.8 fold as compared to the control level is indicative of the presence of cancer in the subject to be diagnosed, preferably a level of anti-YB-1 antibodies in the sample of the patient to be of cancer in the subject to be diagnosed, more preferably a level of anti-YB-1 antibodies in the sample of the patient to be diagnosed of less than 0.65 fold as compared to the control level is indicative of the presence of cancer in the subject to be diagnosed; yet further preferred a level of anti-YB- 1 antibodies in the sample of the patient to be diagnosed of less than 0.6 fold as compared to the control level is indicative of the presence of cancer in the subject to be diagnosed.
  • the invention also pertains to a method for diagnosis of a cancer, wherein the level of antibodies against YB-1 is determined in a sample from a subject to be diagnosed, and wherein a level of anti-YB-1 antibodies below 5 units/ml is indicative of cancer, preferably below 4 units/ml, more preferably below 3.5 units/ml, further preferred below 3 units/ml.
  • the present invention also relates to a method for detecting an anti-YB-1 antibody in a sample from a subject, comprising the steps of
  • the assay is preferably an immunoassay.
  • YB-1 or an antigenic peptide fragment thereof can thus be used for the diagnosis of cancer.
  • the present invention further relates to research and/or diagnostic kit for the diagnosis of cancer or for the prediction of response or non-response in a patient, wherein the kit comprises Y box binding protein 1 (YB-1) or an antigenic (immunogenic) peptide fragment thereof. correlates with the risk of relapse in subjects treated with a chemotherapeutic drug. Decreased levels of anti-YB-1 antibodies in samples correlated with a higher risk of relapse in patients treated with said chemotherapeutic drug. Hence, levels of anti-YB-1 antibodies in samples of patients to be treated with a chemotherapeutic drug are an indicator for response or non-response of a patient, i.e.
  • the present invention provides a method to predict whether a subject will respond or not to a certain treatment, e.g. a treatment with a chemotherapeutic drug.
  • the present invention also relates to method for predicting whether a subject being treated or to be treated for cancer with a drug will respond to said treatment comprising the steps of
  • the first anti-YB-1 antibody control level is derived from one or more subjects responding to said treatment
  • a decreased level in the sample from the subject to be treated as compared to the first anti-YB-1 antibody control level and/or an equal level as compared to the second anti- YB-1 antibody control level is indicative of a non-response of said subject to said treatment
  • an increased level in the sample from the subject to be treated as compared to the second anti-YB-1 antibody control level and/or an equal level as compared to the first anti-YB-1 antibody control level is indicative of a response of said subject to said treatment.
  • determine response of a subject is performed before the onset of treatment.
  • the treatment comprises the administration of a drug, preferably a chemotherapeutic drug.
  • Preferred chemotherapeutic drugs are platinum-based antineoplastic drugs (e.g. platinum analogues), e.g. as further defined herein.
  • the present invention also relates to method for predicting whether a subject being treated or to be treated for cancer with a platinum-based antineoplastic will respond to said treatment comprising the steps of
  • the first anti-YB-1 antibody control level is derived from one or more subjects responding to said treatment
  • a decreased level in the sample from the subject to be treated as compared to the first anti-YB-1 antibody control level and/or an equal level as compared to the second anti- YB-1 antibody control level is indicative of a non-response of said subject to said treatment
  • an increased level in the sample from the subject to be treated as compared to the second anti-YB-1 antibody control level and/or an equal level as compared to the first anti-YB-1 antibody control level is indicative of a response of said subject to said treatment.
  • ratios may be used in order to determine response or non-response to a treatment with a platinum-based antineoplastic.
  • a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of less than 0.9 fold as compared to the first anti-YB-1 antibody control level is indicative of a non-response of said subject to said treatment
  • a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of less than 0.8 fold as compared to the first anti-YB-1 antibody control level is indicative of a non-response of said subject to said treatment
  • further preferred a level of antibodies against Y box binding protein 1 in the 1 antibody control level is indicative of a non-response of said subject to said treatment.
  • ratios may alternatively or additionally be determined to the second control level, in such embodiment a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.1 fold as compared to the second anti- YB-1 antibody control level is indicative of a response of said subject to said treatment; preferably a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.2 fold as compared to the second anti-YB-1 antibody control level is indicative of a response of said subject to said treatment; further preferred a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.3 fold as compared to the second anti-YB-1 antibody control level is indicative of a response of said subject to said treatment; yet further preferred a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.35 fold as compared to the second anti-YB-1 antibody control level is indicative of a response of said subject to said treatment.
  • these methods of the present invention may be performed as methods for monitoring cancer treatment efficiency.
  • the levels of anti-YB-1 antibodies in said subject is determined during treatment, i.e. in a subject being treated with said drug.
  • the present invention also relates to a method of treating cancer with a chemotherapeutic drug, e.g. a platinum-based antineoplastic in a subject, comprising determining the level of antibodies against Y box binding protein 1 (YB-1) in a sample from the subject, wherein when the level of anti-YB-1 antibodies in a sample from the subject is above 1.9 units/ml, said chemotherapeutic drug analogue is administered to the subject, preferably above 2.0 units/ml, more preferably above 2.3 units/ml, also preferred above 2.5 units/ml.
  • a chemotherapeutic drug e.g. a platinum-based antineoplastic in a subject
  • the threshold may also be determined as outlined above, hence, the method of treating cancer in a subject may also comprise the method for determining whether a subject being treated or to be treated for cancer with a chemotherapeutic drug will respond to said treatment, wherein the chemotherapeutic drug is administered if the determined levels of as outlined above.
  • the chemotherapeutic drag in accordance with the present invention is preferably a platinum-based anti-neoplastic.
  • results of non-response of a patient to a treatment may be relapse or progression of cancer of the patient.
  • the method for the prediction of risk stratification for relapse in a patient to be treated or being treated for cancer with a drug comprising the steps of
  • the first anti-YB-1 antibody control level is derived from one or more subjects not showing relapse of cancer after treatment with said drug
  • the second anti-YB-1 antibody control level is derived from one or more subjects showing relapse of cancer after treatment with said drug, wherein a decreased level in the sample from the subject being treated as compared to the first anti-YB-1 antibody control level and/or an equal level as compared to the second anti- YB-1 antibody control level is indicative of relapse in the subject, and wherein an increased level in the sample from the subject being treated as compared to the second anti-YB-1 antibody control level and/or an equal level as compared to the first anti-YB-1 antibody control level is indicative of no relapse in the subject.
  • the level in said patient is determined before the onset of treatment.
  • the preferred subject is therefore in this context a subject to be treated with said drug.
  • first YB-1 antibody control level is derived from one or more subjects that did not show relapse or progression of cancer within 12 months after onset of treatment with said drug and the second YB-1 antibody control level is derived from one or more subjects that did show relapse or progression of cancer within 12 months after onset of treatment with said drug.
  • the present invention also relates to a method prediction of risk stratification for relapse of cancer in a patient being treated or to be treated with a chemotherapeutic drug, e.g. a in a sample from the subject, wherein when the level of anti-YB-1 antibodies in a sample from the subject is below 5 units/ml, is indicative of relapse of cancer in the subject.
  • a chemotherapeutic drug e.g. a in a sample from the subject
  • the assay used was the YB-1-AB-ELISA. The p-value is indicated on top. Bars indicate standard error of mean.
  • Fig. 2 ROC-analysis of the sensitivity of the diagnosis of ovarian cancer is plotted against the specificity.
  • the assay used was the YB-l-AB-ELISA.
  • the graph displays the relation between sensitivity and specificity for an exemplary cutoff value (2.77 units/ml).
  • the assay used was the YB-l -AB-ELISA of Example 1. The p-value is indicated on top. Bars indicate standard error of mean.
  • Fig. 5 ROC-analysis of the sensitivity of the prediction of relapse is plotted against the specificity.
  • Fig. 6 Standard curve of the YB-1 -Auto- Antibody ELISA
  • YB-1 Y box binding protein 1
  • the present invention is based on the finding of that levels of the autoimmune-antibodies in subjects have diagnostic and predictive properties.
  • the antibodies to be detected in connection with the present invention are therefore autoantibodies, i.e. those produced by immune system of the subject to be diagnosed, or being or to be treated.
  • the invention relates to a method for the diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against YB-1 in a sample from a subject to be diagnosed; and (ii) comparing the determined level in the sample to a control level of antibodies against YB-1 in samples derived from one or more subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of cancer in the subject.
  • the cancer is an ovarian cancer.
  • the control level is preferably derived from subjects without that specific cancer, i.e. if ovarian cancer is to be diagnosed, the control level shall be derived from subjects without ovarian cancer.
  • control level may be implicated in the used assay for detecting said auto antibodies.
  • the skilled person hence may chose particulars of the assay so that the test is positive for the presence of the antibody in the sample if levels above a certain level is reached and vice versa be negative for the presence of said autoantibody if levels are determined that are below the control value.
  • the method for diagnosis of cancer in a subject comprising the steps of determining the absence or presence of antibodies against Y box binding protein 1 (YB-1) in a sample from a subject to be diagnosed, wherein absence of YB-1 antibodies in the sample from the subject to be diagnosed are indicative of the presence of cancer in said patient, preferably for the presence of ovarian cancer.
  • YB-1 Y box binding protein 1
  • anti-YB-1 antibody YB-1 antibody
  • YB-1 antibody YB-1 antibody
  • YB-1 auto-antibody refers to the antibodies present in subjects that specifically bind to YB-1 or an immunogenic fragment thereof.
  • specific binding refers to antibodies raised against peptides derived from YB-1. Such peptides can comprise additional or less N- or C-terminal amino acids.
  • An antibody is considered to be specific to YB-1 or an immunogenic peptide thereof, if its affinity towards the variant it is at least 50- fold higher, preferably 100-fold higher, more preferably at least 1000-fold higher than towards other proteins or peptides. It is well known in the art how to determine binding of antibodies to a specific antigen.
  • Cancer in connection with the present invention is to be understood as any diseases involving unregulated cell growth. Cancer in this regard is a disease where cells divide and grow uncontrollably resulting in the formation of malignant tumors.
  • cancer refers to an ovarian cancer.
  • the cancer according to the present invention is an ovarian cancer.
  • Ovarian cancer often derives from the epithelium of the ovary, but may also be derived from fallopian tube.
  • the method of the present invention is predictive for the presence of cancer or the response to a certain treatment.
  • cancer is an ovarian cancer, the ovarian cancer being epithelial ovarian cancer or cancer derived from the fallopian tube.
  • the present application relates to a method for diagnosis of ovarian cancer, comprising the steps of (i) determining the level of antibodies against Y box binding protein 1 (YB-1) in a sample from a subject to be diagnosed, and (ii) comparing the determined level in the sample to a control level of YB-1 antibodies derived from one or more subjects without cancer, preferably without ovarian cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of the presence of ovarian cancer in the subject to be diagnosed
  • the invention further pertains to a method for diagnosis of a ovarian cancer, wherein a level of anti-YB-1 antibodies in the sample of the patient to be diagnosed of less than 0.8 fold as compared to the control level is indicative of the presence of ovarian cancer in the subject to be diagnosed, preferably a level of anti-YB-1 antibodies in the sample of the patient to be diagnosed of less than 0.7 fold as compared to the control level is indicative of the presence of ovarian cancer in the subject
  • the invention also pertains to a method for diagnosis of ovarian cancer, wherein the level of antibodies against YB-1 is determined in a sample from a subject to be diagnosed and wherein a level of anti-YB-1 antibodies below 5 units/ml is indicative of ovarian cancer in the patient to be diagnosed, preferably below 4 units/ml, more preferably below 3.5 units/ml, further preferred below 3 units/ml.
  • the subject to be diagnosed is a mammal, preferably a human.
  • the subject is preferably a human suspected to have cancer.
  • the subject is a female mammal, preferably a female human subject suspected of having ovarian cancer or a female mammal, preferably a female human subject to be screened for the presence of ovarian cancer, preferably a female human subject to be treated or being treated for ovarian cancer with a drug, preferably a chemotherapeutic drug, e.g. a platinum-based antineoplastic drug.
  • YB or “YBX1” or “YB-1” are interchangeably used herein and refer to "Y box binding protein 1", “Y-box transcription factor” or “nuclease-sensitive element-binding protein 1”, and are also known as BP-8; CSDB; DBPB; CSDA2; NSEP1 ; NSEP-1 ; or MDR-NF1.
  • This protein is a protein that in humans is encoded by the YBX1 gene (Entrez Gene ID: 4904).
  • the subject is preferably a human.
  • YB-1 is a cold shock protein.
  • YB-1 lacks an N- terminal signal peptide motif and therefore it s secretion is regulated similar to that of other leaderless proteins. Further to the full-length YB-1 protein which is 324 amino acids in length, a truncated fragment could be detected (Frye et al.; Ybox-protein-1 is actively reports 2009, 10(7):783-789).
  • the "YB-1" may be present in its natural cellular environment and can be used together with the material associated with YB-1 in its natural state as well as in isolated form with respect to its primary, secondary and tertiary structures.
  • the YB-1 is well known to those skilled in the art.
  • the protein or its immunogenic fragment is preferably used in isolated form, i.e. essentially free of other proteins, lipids, carbohydrates or other substances naturally associated with YB-1. "Essentially free of means that the protein or its immunogenic fragment is at least 75%, preferably at least 85%, more preferably at least 95% and especially preferably at least 99% free of other proteins, lipids, carbohydrates or other substances naturally associated with YB-1.
  • the naturally occurring protein as well as all modifications, mutants or derivatives of the YB-1 can be used. This includes all naturally present modifications as known to the killed person.
  • a YB-1 produced by means of recombinant techniques which includes amino acid modifications, such as inversions, deletions, insertions, additions etc. can be used according to the invention provided that this part of the essential function of the YB-1 is present, namely the capability of binding antibodies.
  • the YB-1 being used may also comprise exceptional amino acids and/or modifications of such as alkylation, oxidation, thiol-modification, denaturation, oligomerization and the like.
  • the YB-1 can also be synthesized by chemical means.
  • the YB-1 particularly can be a protein and/or peptide or a fusion protein, which in addition to other proteins, peptides or fragments thereof, includes the YB- 1 as a whole or in part.
  • peptides or polypeptides of the YB-1 which have functionally analogs, analogous properties can be determined by those skilled in the art.
  • polypeptides or peptides have 50-60%, 70% or 80%, preferably 90%, more preferably 95%, and most preferably 98% sequence homology to peptides identified as YB-1, and said homology can be determined, e.g.
  • peptide or polypeptide of an YB-1 used in the present invention comprises also molecules differing from the original sequence by deletion(s), insertion(s), substitution(s) and/or other modifications well known in the prior art and/or comprising a fragment of the original amino acid molecule, the YB-1 still exhibiting the properties mentioned above.
  • a peptide has preferably at least a length of 57 amino acid residues but may also be shorter, e.g. at least 12, 15, 20 or 25 amino acid residues in length. Also included are allele variants and modifications.
  • YB-1 One preferred sequence of YB-1 are given herein, i.e. SEQ ID NO: l for full-length YB-1.
  • the YB-1 may be glycosylated in vivo.
  • all of the above illustrated modifications of the YB-1 will be referred to as "functionally analogous peptides or proteins” or “immunogenic peptides” or “antigenic peptides” in brief.
  • the antibodies to be detected or determined according to the present invention are directed against YB-1. This means that the antibodies specifically bind YB-1. Specific binding of an antibody normally occurs via binding of a binding site of the antigen.
  • the antibodies of the present invention are those specifically binding to YB-1 or immunogenic fragments thereof. This binding may occur via recognition of sequence or structural epitopes. The skilled person is aware of methods of how determining specific epitopes, e.g. fragments of the antigen YB-1, which are recognized and bound by the antibodies to be determined. Fragments of YB-1 binding to the autoantibodies are called immunogenic or antigenic fragments.
  • anti-YB-1 antibodies are understood as any immunoglobulin specifically recognizing/binding to YB-1.
  • the antibody to be detected in a preferred embodiment binds any of YB- 1 , preferably to a sequence comprising or consisting of SEQ ID NO: 1.
  • the anti-YB-1 antibody may particularly be selected from the group of IgA-antibody, IgG-antibody and IgM-antibody, preferably an IgG antibody, e.g. IgGl, IgG2, IgG3 and IgG4.
  • control levels as disclosed herein refer to control levels of YB-1 antibodies. It will be readily understood by the skilled person that the control levels from subjects having the desired disease or response as defined in the methods and to which the determined levels are determined levels. Nevertheless, control levels may be determined in parallel. The skilled person with the disclosure of the present invention and his knowledge is able to determine such levels, as outlined herein. Hence, the control levels of the present invention may be previously defined thresholds or cut off values. Preferred thresholds are disclosed herein. Furthermore, it will be acknowledged by the skilled person that control levels are, like the levels to be determined in the subject to be diagnosed or treated, determined in samples of the recited subjects having the desired disease or response or being healthy. Preferably, the sample is the same kind of sample as the sample of the person to be diagnosed or to be treated, e.g. when the sample of the latter is serum, the control levels are preferably derived from serum samples of the control subjects.
  • the levels of YB-1 antibodies in samples of the patient to be diagnosed and treated or to be treated are compared with the control groups as defined herein. However, in one embodiment the levels are compared to fixed values, i.e. thresholds under or over which a certain diagnosis, or prognosis of response is given.
  • unit- standards may be applied.
  • the inventors of the present invention set out such standard for the YB-1 antibody using a serum sample from a systemic sclerosis patient.
  • Systemic sclerosis patients are known to have high levels of autoimmune antibodies in general. Hence, the inventors took a serum sample of a systemic sclerosis patient for the unit standard met herein.
  • unit/ml refers to the concentration of antibodies standardised as exemplified herein.
  • 20 units/ml refers to a dilution of 1 :200 of a serum sample of systemic sclerosis patients.
  • the serum sample may be derived from a single patient.
  • the inventors of the present invention found that the concentration of YB-1 antibodies in samples of systemic sclerosis do not differ by more than about 10 %, showing such standard being reproducible.
  • the standard for the concentrations of the sclerosis patient is diluted (a) 1 :200 for standard point 20 Units/ml, (b) 1 :400 for standard point 10 Units/ml, (c) 1 :800 for standard point 5 Units/ml, (d) 1 : 1600 for standard point 2.5 Units/ml, (e) 1 :3200 for standard point 1.25 Units/ml and (f) 1 :6400 for standard point 0.63 Units/ml .
  • “Equal” level in context with the present invention means that the levels differ by not more than ⁇ 10 %, preferably by not more than ⁇ 5 %, more preferably by not more than ⁇ 2 %.”
  • Decreased” or “increased” level in the context of the present invention mean that the levels differ by more than 10 %, preferably by more than 15 %, preferably more than 20 %.
  • the sample of the subject to be diagnosed in which the level of anti-YB-1 antibodies is to be determined is preferably a bodily fluid such as whole blood or lymph or fractions of blood such as serum or plasma.
  • the sample is plasma or serum.
  • the sample may need to be homogenized, or extracted with a solvent prior to use in the present invention in order to obtain a liquid sample.
  • a liquid sample hereby may be a solution or suspension.
  • Liquid samples may be subjected to one or more pre-treatments prior to use in the present invention. Such pre-treatments include, but are not limited to dilution, filtration, centrifugation, concentration, sedimentation, precipitation, and dialysis. Pre-treatments may also include the addition of chemical or biochemical substances to the solution, such as acids, bases, buffers, salts, solvents, reactive dyes, detergents, emulsifiers, chelators.
  • “Plasma” in the context of the present invention is the virtually cell-free supernatant of blood containing anticoagulant obtained after centrifugation.
  • anticoagulants such as heparinates or hirudin.
  • Cell-free plasma can be obtained by centrifugation of the anticoagulated blood (e.g. citrated, EDTA or heparinized blood) for at least 15 minutes at 2000 to 3000 g.
  • “Serum” is the liquid fraction of whole blood that is collected after the blood is allowed to clot. When coagulated blood (clotted blood) is centrifuged serum can be obtained as supernatant. It does not contain fibrinogen, although some clotting factors remain.
  • the anti-YB-1 antibody is preferably detected in an immunoassay.
  • Suitable immunoassays may be selected from the group of immunoprecipitation, enzyme immunoassay (EIA)), enzyme-linked immunosorbenassys (ELISA), radioimmunoassay (RIA), fluorescent immunoassay, a chemiluminescent assay, an agglutination assay, nephelometric assay, turbidimetric assay, a Western Blot, a competitive immunoassay, a noncompetitive immunoassay, a homogeneous immunoassay a heterogeneous immunoassay, a bioassay and a reporter assay such as a luciferase assay.
  • the immunoassay is an enzyme linked immunosorbent assay (ELISA).
  • the immunoassays can be homogenous or heterogeneous assays, competitive and non- competitive assays.
  • the assay is in the form of a sandwich assay, which is a non-competitive immunoassay, wherein the anti-YB-1 antibody (i.e. the "analyte") to be detected and/or quantified is allowed to bind to an immobilized YB-1 protein or immunogenic peptide fragment thereof and to a secondary antibody.
  • the YB-1 or fragment thereof i.e. a peptide
  • the secondary antibody is an antibody which is labeled, e.g. with a dye, with a radioisotope, or a reactive or catalytically active moiety such as a peroxidase, e.g. horseradish peroxidase.
  • the amount of labeled antibody bound to the analyte is then measured by an appropriate method.
  • the general composition and procedures involved with "sandwich assays" are well-established and known to the skilled person (The Immunoassay Handbook, Ed. David Wild, Elsevier LTD, Oxford; 3rd ed.
  • the detectable label may for example be based on fluorescence or chemiluminescence.
  • the labelling system comprises rare earth cryptates or rare earth chelates in combination with a fluorescence dye or chemiluminescence dye, in particular a dye of the cyanine type.
  • fluorescence based assays comprise the use of dyes, which may for instance be selected from the group comprising FAM (5-or 6-carboxyfluorescein), VIC, NED, Fluorescein, Fluoresceinisothiocyanate (FITC), IRD-700/800, Cyanine dyes, such as CY3, CY5, CY3.5, CY5.5, Cy7, Xanthen, 6-Carboxy-2',4',7',4,7- hexachlorofluorescein (HEX), TET, 6-Carboxy-4',5'-dichloro-2',7'-dimethodyfluorescein (JOE), N,N,N',N'-Tetramethyl-6-carboxyrhodamine (TAMRA), 6-Carboxy-X-rhodamine (ROX), 5-Carboxyrhodamine-6G (R6G5), 6-carboxyrhodamine-6G (RG6), Rhod
  • chemiluminescence based assays comprise the use of dyes, based on the physical principles described for chemiluminescent materials in Kirk- Othmer, Encyclopedia of chemical technology, 4 th ed., executive editor, J. I. Kroschwitz; editor, M. Howe-Grant, John Wiley & Sons, 1993, vol.15, p. 518-562, incorporated herein by reference, including citations on pages 551 -562.
  • Preferred chemiluminescent dyes are acridiniumesters.
  • the "sensitivity” of an assay relates to the proportion of actual positives which are correctly identified as such, i.e. the ability to identify positive results (true positives positive results / number of positives). Hence, the lower the concentrations of the analyte that can be detected with an assay, the more sensitive the immunoassay is.
  • the "specificity” of an assay relates to the proportion of negatives which are correctly identified as such, i.e. the ability to identify defined as the ability of an individual antigen binding site to react with only one antigenic epitope.
  • the binding behaviour of an antibody can also be characterized in terms of its "affinity” and its "avidity".
  • the "affinity” of an antibody is a measure for the strength of the reaction between a single antigenic epitope and a single antigen binding site.
  • the “avidity” of an antibody is a measure for the overall strength of binding between an antigen with many epitopes and multivalent antibodies.
  • immunogenic peptide or "antigenic peptide” as used herein is a portion of an YB-1 protein that is recognized (i.e., specifically bound) by the anti-YB-1 antibody.
  • immunogenic peptides generally comprise at least 5 amino acid residues, more preferably at least 10, and still more preferably at least 20 amino acid residues of YB-1. However, they may also comprise at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 amino acid residues.
  • YB-1 by expression in cells, preferably eukaryotic cells or in cell free, preferably eukaryotic cell free systems.
  • YB-1 may be present in its natural cellular environment and can be used together with the material associated with the protein in its natural state as well as in isolated form.
  • Suitable expression systems include prokaryotic cells (e.g. E. coli) or eukaryotic cells (e.g. mammalian cells such asChinese hamster ovary (CHO) cells) overexpressing the human YB-1.
  • Cell extracts or purified protein can be used to detect anti-YB-1 antibodies.
  • the isolated protein should account for at least 0.5%, preferably at least 5% more preferably at least 25%, and in a particular preferred embodiment at least 50%.
  • the protein is preferably used in isolated form, i.e. essentially free of other proteins, lipids, carbohydrates or other substances naturally associated with the YB-1. "Essentially free of means that the protein is at least 75%, preferably at least 85%, more preferably at least 95% and especially preferably at least 99% free of other proteins, lipids, carbohydrates or other substances naturally associated with the protein.
  • the determining steps of the methods according to the present invention comprise the steps of
  • the invention relates to a method for detecting an anti-YB-1 antibody in a sample from a subject, comprising the steps of
  • the YB-1 or the antigenic peptide fragment thereof may preferably be immobilized on a surface.
  • the YB-1 or the antigenic peptide fragment thereof is immobilized directly on a surface.
  • "Direct" immobilization in context with the present invention relates to an immobilization without using tags fused to the YB-1, e.g. without YB-1 being fused to a GST-Tag.
  • a direct immobilization to the surface means that the protein is not fused to a tag. Such tag may interfere with the conformation of the protein that could cause the autoantibodies to be detected no longer binding to the protein.
  • conformation stabilizing means are preferred in context with the methods according to the invention.
  • the YB-1 is immobilized directly on a surface or stabilized by a buffer covering the surface, the buffer comprising Calcium chloride
  • the YB-1 is immobilized directly on a surface and stabilized by a buffer covering the surface, the buffer comprising Calcium chloride.
  • the Calcium chloride concentration of the buffer may vary, however it shall stabilize the protein to allow proper binding of antibodies to the YB-1.
  • the Calcium chloride concentration is from 0.1 mM to 10 mM, further preferred from 0.5 to 5 mM, particularly preferred 1 mM.
  • the Calcium chloride may that come into contact with the YB-1 protein, e.g. also washing and/or detection buffers.
  • the complex may for example be detected using a secondary antibody against the Fc portion of the anti-YB-1 antibody.
  • the secondary antibody may be an anti-IgG antibody.
  • the anti-YB- 1 antibody to be detected is an IgG-antibody and the secondary antibody is an anti-IgG antibody, particularly preferred the subject is a human and the second antibody is an anti-human-IgG antibody.
  • the secondary antibody is an anti-human-total IgG antibody. Nevertheless, in some embodiment it may be preferred that the subtypes are differentially detected.
  • the subject is a human and
  • the anti-YB-1 antibody is an IgG 1 -antibody and the secondary antibody is an anti- human-IgGl antibody;
  • the anti-YB-1 antibody is an IgG2-antibody and the secondary antibody is an anti- human-IgG2 antibody;
  • the anti-YB-1 antibody is an IgG3-antibody and the secondary antibody is an anti- human-IgG3 antibody;
  • the anti-YB-1 antibody is an IgG4-antibody and the secondary antibody is an anti- human-IgG4 antibody.
  • the secondary antibody may for example be labeled with a detectable marker, e.g. a peroxidase.
  • parameters of the subject may be considered as well for diagnosis, differential diagnosis, prognosis of response etc.
  • Such parameters in a multivariate model may include gender, age, histological evaluation, Figo or histopathological staging, grading of the tumor and other markers.
  • Dependent variables for determining survival may also be time till death, time till first relapse, time till death or first relapse (shorter interval if both events occurred).
  • a Cox -Proportional-Hazard regression predictors can either be measures (as e.g. level of a biomarker) or categorical data (as e.g. response to a previous treatment).
  • diagnostic markers only give a certain degree of sensitivity and specificity, as also outlined herein. He knows that different further parameters might be considered in order to increase both. For example, when detecting levels of a marker indicative of epithelial cancer, inter alia ovarian cancer, the skilled person would not diagnose ovarian cancer in a male human subject. Nevertheless, the present invention provides a new and superior marker for diagnosis, prognosis of cancer, particularly for ovarian cancer. In the context of the methods of the invention and particularly the immunoassays of the invention, the presence of one or more further diagnostic markers for ovarian cancer is detected in the sample.
  • a diagnostic method of the present invention levels of CA125, Human Epidymis Protein 4 (HE4) and/or Mesothelin are detected in addition.
  • the invention also relates to the use of YB-1 or an antigenic peptide fragment thereof, preferably as set out herein above, for the diagnosis of cancer, preferably for the diagnosis of an YB-1 or YB-1 associated cancer, more preferably for the diagnosis of ovarian cancer.
  • the YB-1 or the antigenic peptide fragment thereof may preferably be immobilized on a surface.
  • the YB-1 or the antigenic peptide fragment thereof is immobilized directly on a surface.
  • Direct immobilization in context with the present invention relates to an immobilization without using tags fused to the YB-1 , e.g. without YB-1 being fused to a GST-Tag.
  • a direct immobilization to the surface means that the protein is not fused to a tag. Such tag may interfere with the conformation of the protein that could cause the autoantibodies to be detected no longer binding to the protein.
  • conformation stabilizing means are preferred in context with the methods according to the invention.
  • the YB-1 is immobilized directly on a surface or stabilized by a buffer covering the surface, the buffer comprising Calcium chloride
  • the YB-1 is immobilized directly on a surface and stabilized by a buffer covering the surface, the buffer comprising Calcium chloride.
  • the Calcium chloride concentration of the buffer may vary, however it shall stabilize the protein to allow proper binding of antibodies to the YB-1. In a preferred preferred from 0.5 to 5 mM, particularly preferred 1 mM.
  • the Calcium chloride may in a preferred embodiment be added to any buffer of the methods of the present invention that come into contact with the YB-1 protein, e.g. also washing and/or detection buffers.
  • the levels of the anti-YB-1 antibodies a may be analyzed in a number of fashions well known to a person skilled in the art. For example, each assay result obtained may be compared to a "normal" value, or a value indicating a particular disease or outcome. A particular diagnosis/prognosis may depend upon the comparison of each assay result to such a value, which may be referred to as a diagnostic or prognostic "threshold".
  • assays for one or more diagnostic or prognostic indicators are correlated to a condition or disease by merely the presence or absence of the indicator(s) in the assay. For example, an assay can be designed so that a positive signal only occurs above a particular threshold concentration of interest, and below which concentration the assay provides no signal above background.
  • ROC curves Receiver Operating Characteristic curves
  • the area under the ROC curve is a measure of the probability that the perceived measurement will allow correct identification of a condition.
  • ROC curves can be used even when test results don't necessarily give an accurate number.
  • a threshold is selected to provide a ROC curve area of greater than about 0.5, more preferably greater than about 0.7, still more preferably greater than about 0.8, even more preferably greater than about 0.85, and most preferably greater than about 0.9.
  • the term "about” in this context refers to +/- 5% of a given measurement.
  • the horizontal axis of the ROC curve represents (1 -specificity), which increases with the rate of false positives.
  • the vertical axis of the curve represents sensitivity, which increases with the rate of true positives.
  • the value of (1- specificity) may be determined, and a corresponding sensitivity may be obtained.
  • the area under the ROC curve is a measure of the probability that the measured marker level will allow correct identification of a disease or condition. Thus, the area under the ROC curve can be used to determine the effectiveness of the test.
  • a positive likelihood ratio, negative likelihood ratio, odds ratio, or hazard ratio is used as a measure of a test's ability to predict risk or diagnose a disease.
  • a value of 1 indicates that a positive result is equally likely among subjects in both the "diseased" and "control" groups; a value greater than 1 indicates that a positive result is more likely in the diseased group; and a value less than 1 indicates that a positive result is more likely in the control group.
  • a value of 1 indicates that a negative result is equally likely among subjects in both the "diseased" and "control" groups; a value greater than 1 indicates that a negative result is more likely in the test group; and a value less than 1 indicates that a negative result is more likely in the control group.
  • a value of 1 indicates that a positive result is equally likely among subjects in both the "diseased" and “control” groups; a value greater than 1 indicates that a positive result is more likely in the diseased group; and a value less than 1 indicates that a positive result is more likely in the control group.
  • a value of 1 indicates that the relative risk of an endpoint (e.g., that the risk is greater in the diseased group; and a value less than 1 indicates that the risk is greater in the control group.
  • associating a diagnostic or prognostic indicator, with a diagnosis or with a prognostic risk of a future clinical outcome is a statistical analysis. For example, a marker level of lower than X may signal that a patient is more likely to suffer from an adverse outcome than patients with a level more than or equal to X, as determined by a level of statistical significance.
  • a change in marker concentration from baseline levels may be reflective of patient prognosis, and the degree of change in marker level may be related to the severity of adverse events.
  • Statistical significance is often determined by comparing two or more populations, and determining a confidence interval and/or a p value. See, e.g., Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983.
  • Preferred confidence intervals of the invention are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, while preferred p values are 0.1 , 0.05, 0.025, 0.02, 0.01, 0.005, 0.001 , and 0.0001.
  • Suitable threshold levels for the stratification of subjects into different groups have to be determined for each particular combination of YB-1 -antibodies, disease and/or medication. This can e.g. be done by grouping a reference population of patients according to their level of YB-1 -antibodies into certain quantiles, e.g. quartiles, quintiles or even according to suitable percentiles. For each of the quantiles or groups above and below certain percentiles, hazard ratios can be calculated comparing the risk for an adverse outcome, i.e. an "cancer” or a "non response", e.g.
  • a hazard ratio (HR) above 1 indicates a higher risk for an adverse outcome for the patients who have received a treatment than for patients who did not.
  • a FIR below 1 indicates beneficial effects of a certain treatment in the group of patients.
  • a HR around 1 (e.g. +/- 0.1) indicates no elevated risk but also no benefit from medication for the particular group of patients.
  • relapse and/or mortality upon treatment with an platinum- based antineoplastic will affect patients with high levels (e.g. in the fifth quintile) of YB-1- antibodies, while in other cases only patients with low levels of YB-1 -antibodies will be affected (e.g. in the first quintile).
  • a skilled person is able to identify those groups of patients having cancer, those groups that do respond to a medication and those groups that do not respond to the medication.
  • the gist of the invention is the correlation of reduced antibody levels against YB-1 with a certain outcome as outlined herein. Exemplarily, some combinations of medications are listed for several diseases in the appended examples.
  • the diagnosis, risk for relapse of cancer and/or outcome for a patient are determined by relating the patient's individual level of marker antibody to certain percentiles (e.g. 20 th , 10 th , 5 th or 2.5 th percentile) of a healthy population or responders, respectively.
  • percentiles e.g. 20 th , 10 th , 5 th or 2.5 th percentile
  • Kaplan-Meier estimators may be used for the assessment or prediction of the outcome or risk (e.g. diagnosis, relapse, progression or morbidity) of a patient.
  • drug in connection with the present invention is to be understood as any substance, pharmaceutical composition or the like which are intended for the treatment of cancer, preferably ovarian cancer.
  • drugs are known.
  • Preferred drugs are chemotherapeutic agents or chemotherapeutic drugs, preferably platinum analogues used for treating cancer.
  • platinum analogues are known by the skilled person and are preferably platinum-based antineoplastic agents, preferably selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, Nedaplatin, Triplatin, and Lipoplatin.
  • a method of treating cancer e.g.
  • the invention encompasses a method of treating ovarian cancer in a subject, comprising determining the level of antibodies against YB-1 in a sample from the above a level determined as the control level for no-response to the treatment with a method according to the present invention as disclosed herein above.
  • the invention encompasses a method of treating ovarian cancer in a subject, comprising determining the level of antibodies against YB-1 in a sample from the subject, wherein when the level of anti-YB-1 antibodies in a sample from the subject is above 1.9 units/ml, said chemotherapeutic drug analogue is administered to the subject, preferably above 2.0 units/ml, more preferably above 2.3 units/ml, also preferred above 2.5 units/ml.
  • Drugs used in the treatment of cancer include platinum analogues, e.g. an platinum-based antineoplastic, preferably selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, Nedaplatin, Triplatin, and Lipoplatin.
  • platinum analogues e.g. an platinum-based antineoplastic, preferably selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, Nedaplatin, Triplatin, and Lipoplatin.
  • the invention also relates a drug for use in the treatment of cancer, preferably ovarian cancer, in a subject, wherein the drug is administered to the subject when the level anti-YB- 1 antibodies in a sample from the subject is above a level determined as the control level for non-response to the treatment with a method according to the present invention as disclosed herein above.
  • the invention relates to a drug for use in the treatment of cancer in a subject, wherein the drug is administered to the subject when the level anti-YB-1 antibodies in a sample from the subject is above 1.9 units/ml, said chemotherapeutic drug analogue is administered to the subject, preferably above 2.0 units/ml, more preferably above 2.3 units/ml, also preferred above 2.5 units/ml.
  • the invention relates to a drug, preferably a platinum-based antineoplastic, for use in the treatment of cancer, preferably ovarian cancer, in a subject, wherein the drug is administered to the subject if a level of antibodies against Y box binding protein 1 in a sample from the subject to be treated of more than 1.1 fold as compared to anti-YB-1 antibody control levels derived from samples of patients not responding to said treatment is determined; preferably if a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.2 fold as compared to the anti-YB-1 antibody control level is determined; further preferred if a level of antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.3 fold as compared to antibodies against Y box binding protein 1 in the sample from the subject to be treated of more than 1.35 fold as compared to the anti-YB-1 antibody control level is determined.
  • a drug preferably a platinum-based antineoplastic
  • cancer e.g. the cancer preferably being an ovarian cancer
  • the subject being a human, preferably a female human.
  • the drug is for use in the treatment of ovarian cancer.
  • the drug is preferably a platinum analogue, such as a platinum-based antineoplastic, preferably selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, Nedaplatin, Triplatin, and Lipoplatin.
  • the invention also relates to platinum-based antineoplastic for use in the treatment of ovarian cancer in a subject, wherein bevacizumab is administered to the subject when the level anti-YB-1 antibodies in a sample from the subject is above 1.9 units/ml, said chemotherapeutic drug analogue is administered to the subject, preferably above 2.0 units/ml, more preferably above 2.3 units/ml, also preferred above 2.5 units/ml.
  • Antineoplastic in connection with the present invention relates to substances acting to prevent, inhibit or halt the development of a neoplasm (a tumor), i.e. an agent with antineoplastic properties.
  • the invention also pertains to a research and/or diagnostic kit for the diagnosis of cancer, e.g. ovarian cancer, or for the prediction or risk stratification for relapse of cancer in a patient, wherein the kit comprises YB-1 or an antigenic peptide fragment thereof.
  • the kit may further comprise an antibody directed to the Fc portion of the anti-YB-1 antibody to be detected, i.e. an anti-human IgG antibody.
  • kits can comprise a carrier, package or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in the method.
  • the kit of the invention will typically desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • a label can be provided on the container to indicate that the composition is used for a specific therapeutic or non- therapeutic application, and can also indicate directions for either in vivo or in vitro use, such as those described herein. Directions and or other information can also be included on an insert which is included with the kit.
  • the invention hence also relates to a kit for diagnosing cancer, e.g. ovarian cancer, as outlined above, or predicting the response of a cancer patient to the treatment for cancer, e.g. ovarian cancer by e.g. a platinum-based antineoplastic, said kit comprising the YB-1 protein or an antigenic peptide thereof, and means to detect antibodies binding to said YB-1 or antigenic peptide thereof.
  • conformation stabilization of the YB-1 is preferred, hence, in a preferred embodiment the kit of the comprises YB-1 or an antigenic peptide fragment thereof immobilized on a surface; preferably immobilized directly on a surface.
  • the YB-1 is immobilized directly on a surface or stabilized by a buffer covering the surface, the buffer comprising Calcium chloride
  • the YB-1 is immobilized directly on a surface and stabilized by a buffer covering the surface, the buffer comprising Calcium chloride.
  • the Calcium chloride concentration of the buffer may vary, however it shall stabilize the protein to allow proper binding of antibodies to the YB-1.
  • the Calcium chloride concentration is from 0.1 mM to 10 mM, further preferred from 0.5 to 5 mM, and particularly preferred 1 mM.
  • the Calcium chloride may in a preferred embodiment be added to any buffer of the kit coming into contact with the immobilized YB-1 protein, e.g. also washing and/or detection buffers.
  • the kit is designed for a method of the present invention.
  • the kit is preferably designed to detect autoimmune antibodies in samples of subject and hence comprises means to detect such antibodies, particularly antibodies binding to said YB-1 or peptide thereof.
  • Such means are outlined herein above, e.g. for immunoassays, and applying likewise to the kit.
  • the embodiments set out for the immunoassays, proteins and methods apply also to the kit of the invention.
  • the kits of the present invention are meant plasma. Hence, in one embodiment they comprise means for the preparation of blood, e.g. for gaining serum thereof.
  • the kit may also comprise means for detecting antibodies, e.g.
  • the kit may comprise control composition and/or standards.
  • the control composition preferably comprises YB-1 antibodies as positive control.
  • the kit may comprise one or a plurality of standard compositions.
  • a standard composition comprises YB-1 antibodies at a defined concentration.
  • determination of concentration of autoimmune-antibodies may be performed using standard curves. These curves set out which concentration of antibodies in a sample or solution corresponds to what read-out value of the assay used, e.g. optical density or proportion of optical density at different wavelengths (e.g. 450nm/620nm).
  • kits of the present invention may comprise one or more standard compositions having a defined concentration of YB-1 antibodies, preferably of the kind to be detected in the method.
  • a standard composition of the kit according to the present invention may for instance comprise YB-1 antibodies at concentrations selected from the group consisting of 20 units/ml, 10 units/ml, 5 units/ml, 2.5 units/ml, 1.25 units/ml, and 0.63 units/ml.
  • the kit comprises six standard compositions with the recited concentration.
  • the kit comprises one standard composition with the highest concentration of the standard curve, e.g. 20 units/ml or 10 units/ml.
  • the other concentrations may be produced at the side of the end user by further dilutions, e.g. in PBS.
  • a dilution buffer may therefore also be comprised in the kits according to the invention.
  • Example 1 YB-1 autoantibody levels in serum samples were measured using two different sandwich ELISA kit (CellTrend GmbH Luckenwalde, Germany).
  • sandwich ELISA kit CellTrend GmbH Luckenwalde, Germany.
  • the microtiter 96- well polystyrene plates were directly coated with human full length YB-1 of the sequence of SEQ ID NO:l .
  • This kit is referred to herein as YB- 1 -AB-ELIS A.
  • 1 mM Calcium chloride was added to every buffer.
  • Duplicate samples of a 1 : 800 serum dilution were incubated at 4°C for 2 hours.
  • YB-1 -autoantibodies are not commercially available; a serum sample from a patient with a systemic sclerosis is used for the standard curve. A 1 :200 dilution of the serum sample is defined as 20 units/ml YB-1 -antibodies. To set a standard for the concentrations of the autoimmune antibodies, a standard curve was generated.
  • a serum sample of systemic sclerosis serum sample was diluted (a) 1 : 200 for standard point 20 units/ml, (b) 1 : 400 for standard point 10 units/ml, (c) 1 : 800 for standard point 5 units/ml, (d) 1 : 1600 for standard point 2.5 units/ml, (e) 1 : 3200 for standard point 1.25 units/ml and (f) 1 : 6400 for standard point 0.63 units/ml. Then the optical density was determined using the kit and method of above. Each standard point was performed in duplicates. Results are shown in Figure 6.
  • Example 2 Example 2:
  • YB-1 antibody levels in serum samples from 132 healthy donors (“Control”) and 198 patients with ovarian cancer (“OvCA”) were measured using the kit and method of example 1. The levels were determined in units/mL.
  • Figure 1 shows the mean values of the natural logarithm (In) of YB-1 antibody levels for OvCA and Control subjects determined using the YB-l-AB- ELISA. Patient suffering from ovarian cancer had significantly lower levels (p ⁇ 0.0001) of anti-YB-1 antibodies as compared to healthy controls.
  • ROC-analysis was performed. The results are shown if Fig. 2 for YB-1-AB-ELISA. The results for YB-l-AB-ELISA clearly show that the use of YB-1 full length protein allows for a good detection of anti-YB-1 antibodies and delivers a diagnostic assay with high sensitivity and specificity.
  • Example 3 Levels of YB-1 antibodies were determined in samples from patients suffering from ovarian cancer taken after surgical removal of the cancer and before onset of treatment with a platinum-based antineoplastic. The patients were treated with a chemotherapeutic agent (platinum-based antineoplastic) after surgical removal of ovarian cancer. YB-1 antibody levels in serum samples from 132 healthy donors ("control"; see Example 2), 1 1 1 patients with ovarian cancer showing response to the treatment with the platinum-based antineoplastic carboplatin ("responder") and 52 patients not showing response to the platinum-based antineoplastic (“non-responder”) were measured using the kit and method of Example 1. The levels were determined in units/mL.
  • Figure 3 shows the mean values of the natural logarithm of the YB-1 antibody levels for control, responder and non-responder subjects. Patients not responding to the treatment with the platinum-based antineoplastic had significantly lower levels (p ⁇ 0.0372) of YB-1 antibodies as compared to patients responding
  • Example 4 Serum samples of ovarian cancer patients were taken before treatment with carboplatin. The treatment was conducted by physicians. The patients were categorized into relapse free ("no relapse") and patients who received a relapse ("relapse"). The levels of YB-1 antibodies were determined as outlined in Example 1. The results are shown in Figure 4. Levels of anti-YB-1 antibodies were lower in patients of the "relapse" group (In mean: 0.985 units/ml) compared to the "no relapse” group (In mean: 0.833 units/ml).
  • the sensitivity and specificity for levels of YB-1 antibodies as predictor of relapse was calculated using ROC-analysis and Kaplan-Meier estimation. Relapse were determined after treatment by surgery and a platinum-based antineoplastic. The results for an exemplary cut off value of 1.74 units/ml are given are given in Figure 5. The results show that the levels of YB-1 antibodies are a good predictor for relapse after treatment of cancer patients, giving a sensitivity of 70 % by maintaining a specificity of 50 %.
  • YB antibody levels are significant lower in patients with cancer compared to healthy controls. This allows diagnosis of cancer. Furthermore, the levels are significantly higher in patients in which show no relapse after treatment as compared to patients showing relapse of cancer after treatment. Levels of YB-1 antibodies in samples are a well suited predictor for the response to the treatment with a platinum-based antineoplastic.

Abstract

La présente invention concerne un procédé de diagnostic d'un cancer, comprenant les étapes consistant (i) à déterminer le niveau d'anticorps contre YB-1 dans un échantillon provenant d'un sujet à diagnostiquer, (ii) à comparer le niveau déterminé dans l'échantillon à un niveau témoin obtenu de sujets sans cancer ; un niveau réduit dans l'échantillon provenant du sujet à diagnostiquer par comparaison au niveau témoin indiquant un cancer chez le sujet. En outre, l'invention concerne un procédé de prédiction de réponse et de résultat d'un traitement d'un cancer avec un anti-néoplasique à base de platine.
PCT/EP2017/063129 2016-05-31 2017-05-31 Diagnostic du cancer par détection d'auto-anticorps dirigés contre la protéine de liaison à la boîte y (yb-1) WO2017207616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172181 2016-05-31
EP16172181.6 2016-05-31

Publications (2)

Publication Number Publication Date
WO2017207616A1 true WO2017207616A1 (fr) 2017-12-07
WO2017207616A9 WO2017207616A9 (fr) 2018-03-22

Family

ID=56119313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/063129 WO2017207616A1 (fr) 2016-05-31 2017-05-31 Diagnostic du cancer par détection d'auto-anticorps dirigés contre la protéine de liaison à la boîte y (yb-1)

Country Status (1)

Country Link
WO (1) WO2017207616A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022200355A1 (fr) 2021-03-24 2022-09-29 Celltrend Gmbh Diagnostic de la maladie d'alzheimer par détection d'auto-anticorps contre la protéine-1 de liaison à la boîte y (yb-1)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064593A2 (fr) * 2001-11-09 2003-08-07 Virginia Mason Research Center Panneaux d'antigenes et procedes d'utilisation associes
US20070077556A1 (en) * 2001-03-23 2007-04-05 Virginia Mason Research Center Tumor associated antigens and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077556A1 (en) * 2001-03-23 2007-04-05 Virginia Mason Research Center Tumor associated antigens and methods of using the same
WO2003064593A2 (fr) * 2001-11-09 2003-08-07 Virginia Mason Research Center Panneaux d'antigenes et procedes d'utilisation associes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022200355A1 (fr) 2021-03-24 2022-09-29 Celltrend Gmbh Diagnostic de la maladie d'alzheimer par détection d'auto-anticorps contre la protéine-1 de liaison à la boîte y (yb-1)

Also Published As

Publication number Publication date
WO2017207616A9 (fr) 2018-03-22

Similar Documents

Publication Publication Date Title
WO2007082144A9 (fr) Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
JP2020515826A (ja) 抗体アッセイ
EP3077825B1 (fr) Procédé de détermination sélective de facteur de croissance placentaire de 2
EP3102944B1 (fr) Diagnostic de cancer par la détection d'auto-anticorps contre le récepteur egf
EP3102943B1 (fr) Diagnostic de cancer par la détection d'auto-anticorps contre le récepteur du facteur de croissance endothéliale vasculaire (vegfr)
US10203343B2 (en) Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (EGF)
WO2017207616A1 (fr) Diagnostic du cancer par détection d'auto-anticorps dirigés contre la protéine de liaison à la boîte y (yb-1)
EP3102946B1 (fr) Diagnostic de cancer par la détection d'auto-anticorps contre le facteur de croissance endothéliale vasculaire (vegf)
CN108738347B (zh) 辅助肝细胞癌患者的再发风险预测的方法、装置、计算机程序制品及试剂盒
US10732184B2 (en) Diagnosis of cancer by detecting auto-antibodies against PAR1
EP3213075B1 (fr) Diagnostic d'une maladie auto-immune par la détection d'anticorps dirigés contre le récepteur c5a
EP4014045B1 (fr) Diagnostic de cancer avec d'auto-anticorps contre pd1 et pd-l1
EP4314834A1 (fr) Diagnostic de la maladie d'alzheimer par détection d'auto-anticorps contre la protéine-1 de liaison à la boîte y (yb-1)
EP3298408B1 (fr) Procédé de diagnostic du syndrome des antiphospholipides par la détermination d'anticorps anti-par1
TW201928351A (zh) 抗體測定

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17728128

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17728128

Country of ref document: EP

Kind code of ref document: A1